Result of GM

Oxford Pharmascience Group plc

("Oxford Pharmascience" or the "Company")

Result of AGM & General Meeting

Oxford Pharmascience Group plc (AIM: OXP), the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, is pleased to announce that at its Annual General Meeting held earlier today all resolutions were duly passed.

At the General Meeting also held earlier today in connection with the placing of 200,000,000 new Ordinary Shares, as announced on 9 June 2015, all resolutions were duly passed.

Placing 

As previously announced the Company has raised gross proceeds of £20 million by way of a placing for new Ordinary Shares at 10 pence each (the "Placing Shares") with new and existing investors.

Admission and Total Voting Rights

Following the successful conclusion to the General Meeting, applications have been made for the 42,915,000 First Placing Shares and the 157,085,000 Second Placing Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on 25 June 2015 and on 26 June 2015 respectively.

Following admission of the First Placing Shares, the issued share capital will consist of 1,048,576,619 Ordinary Shares carrying one vote each. The Company does not hold any shares in Treasury and this figure of 1,048,576,619 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Following admission of the Second Placing Shares, the issued share capital will consist of 1,205,661,619 Ordinary Shares, each carrying one vote; this figure may be used by shareholders from 26 June 2015 as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

The beneficial interests of the Directors in the issued share capital of the Company following admission of all of the Placing Shares (i.e. from 26 June 2015) will be as follows:

Marcelo Bravo, Chief Executive, said:

"We are pleased to be concluding our placing following the strong support shown by both existing shareholders and new investors. With greater access to capital than had originally been sought, we are now able to not only diversify our pipeline with OXPzero™ Asprin which addresses a different therapeutic area, cardiovascular disease, but also to establish more robust data for OXPzero™ Naproxen and OXPzero™ Ibuprofen in the our pain portfolio, as well as explore the potential of our statin product, Safesat™, through proof of concept studies and investigate its potential use in combination with our aspirin product.

With data expected from our OXPzero™ Naproxen studies in early Q3 and the pharmacokinetic data from our OXPzero™ Ibuprofen studies in July followed by endoscopy data in late Q3/early Q4, we will have greater flexibility in our commercial strategy when we enter partnering discussions later this year. This includes the possibility to take a selected NSAID molecule further through development if is likely to result in better value compared to earlier licensing.

We look forward to providing further updates across the broadening portfolio of enhanced medicines."

For further information please contact:

Oxford Pharmascience Group Plc

Marcelo Bravo, Chief Executive +44 20 7554 5875

N+1 Singer (Nominated Adviser & Broker)

Aubrey Powell/Jen Boorer +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not intend to take its products to market directly but license them to leading pharmaceutical companies. 

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines, the Company is able to develop new innovative products in much quicker timescales and without the high risk and cost of failure associated with developing new drugs.